Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7169517 | 0.91 | HPGD (0.65) | HPGDALDH1A1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL13486222 | 0.90 | HPGD (0.71) | HPGDALDH1A1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL108225 | 0.83 | ALDH1A1 (0.90) | HPGDALDH1A1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL5970063 | 0.80 | HPGD (1.00) | HPGDALDH1A1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL244547 | 0.79 | HPGD (1.00) | HPGDALDH1A1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL13486221 | 0.79 | HPGD (1.00) | HPGDALDH1A1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL14140751 | 0.79 | HPGD (1.00) | HPGDALDH1A1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL22226790 | 0.77 | HPGD (0.44) | HPGDALDH1A1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL7464300 | 0.77 | HPGD (0.75) | HPGDALDH1A1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL7433458 | 0.77 | HPGD (0.75) | HPGDALDH1A1HSD17B10CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006034196-A1 | COMPOSITIONS FOR ENHANCING MEMORY AND METHODS THEREFOR | LIFELIKE BIOMATIC INC. (US) | 2006-03-30 | — | — | WO | claimed |
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | LIFELIKE BIOMATIC, INC. (US) | 2006-03-23 | — | — | US | claimed |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | UNIV CASE WESTERN RESERVE (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | UNIV CASE WESTERN RESERVE (US) | 2017-07-27 | — | — | US | disclosed |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2010-02-11 | — | — | US | disclosed |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2010-02-11 | — | — | US | disclosed |
| US-20080176793-A1 | UPREGULATING ACTIVITY OR EXPRESSION OF BDNF TO MITIGATE COGNITIVE IMPAIRMENT IN ASYMPTOMATIC HUNTINGTON'S SUBJECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-07-24 | — | — | US | disclosed |
| US-7235548-B2 | Compounds and their use as positive AMPA receptor modulators | NEUROSEARCH A/S (DK) | 2007-06-26 | — | — | US | disclosed |
| WO-2006034196-A1 | COMPOSITIONS FOR ENHANCING MEMORY AND METHODS THEREFOR | LIFELIKE BIOMATIC INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| EP-1156043-A2 | Drugs that enhance synaptic responses mediated by ampa receptors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-11-21 | — | — | EP | disclosed |
| US-6274600-B1 | COGNITION ACTIVATORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2001-08-14 | — | — | US | disclosed |
| EP-1071426-A2 | NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999042456-A2 | NOVEL COMPOUNDS AND THEIR USE AS POSITIVE AMPA RECEPTOR MODULATORS | NEUROSEARCH A/S (DK) | 1999-08-26 | — | — | WO | disclosed |
| US-5891876-A | ALPHA-AMINO-3-HYDROXY-5-METHYL-ISOXAZOLE-4-PROPIONIC ACID (AMPA); DRUGS THAT ENHANCE THESE RECEPTOR CURRENTS WILL FACILITATE COMMUNICATION IN BRAIN NETWORKS RESPONSIBLE FOR PERCEPTUAL-MOTOR INTEGRATION AND HIGHER ORDER BEHAVIORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-04-06 | — | — | US | disclosed |
| US-5852008-A | Heteroatom substituted benzoyl derivatives that enhance synaptic response mediated by receptors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-12-22 | — | — | US | disclosed |
| US-5747492-A | IMPROVING MEMORY; A-AMINO-3-HYDROXY-5-METHYL ISOOXAZOLE-4-PROPIONIC ACID | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0651746-A1 | DRUGS THAT ENHANCE SYNAPTIC RESPONSES MEDIATED BY AMPA RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-05-10 | — | — | EP | disclosed |
| WO-1994002475-A1 | DRUGS THAT ENHANCE SYNAPTIC RESPONSES MEDIATED BY AMPA RECEPTORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063707-A1 | Compositions for enhancing memory and methods therefor | GRIN1, GRIN3A, GRIN2A | HPGD 1202/4885ALDH1A1 4321/4885HSD17B10 4362/4885 |
| US-20080176793-A1 | UPREGULATING ACTIVITY OR EXPRESSION OF BDNF TO MITIGATE COGNITIVE IMPAIRMENT IN ASYMPTOMATIC HUNTINGTON'S SUBJECTS | BDNF, HTT, NTRK2 | HPGD 2638/4885ALDH1A1 4137/4885HSD17B10 1322/4885 |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, BDNF, NGF | HPGD 3434/4885ALDH1A1 2314/4885HSD17B10 4122/4885 |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | GRM2, GRIN1, GRM3 | HPGD 2407/4885ALDH1A1 1291/4885HSD17B10 2226/4885 |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, NGF, BDNF | HPGD 2739/4885ALDH1A1 2307/4885HSD17B10 3395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.